Abstracts tagged "immunosuppressants"

Abstract Number: 831 • 2016 ACR/ARHP Annual Meeting
Immunosuppression May Prevent Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Marie Hudson², Mianbo Wang³, Russell Steele⁴, Murray Baron⁵ and Canadian Scleroderma Research Group, ¹Division of Rheumatology, Jewish General Hospital, Lady Davis Institute, Montreal, QC, Canada, ²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Mathematics, McGill University, Montreal, QC, Canada, ⁵Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of premature mortality in systemic sclerosis (SSc). Immunosuppression is used for treatment of established disease. However,…
Abstract Number: 839 • 2016 ACR/ARHP Annual Meeting
Immunosuppression Does Not Prevent Severe Gastrointestinal Disease in Systemic Sclerosis
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Severe gastrointestinal (GI) disease is associated with considerable morbidity and high mortality in systemic sclerosis (SSc). There are no known preventative treatments. We wished…
Abstract Number: 283 • 2015 ACR/ARHP Annual Meeting
Altered Serum Fatty Acid Profiles in Patients with Polymyositis or Dermatomyositis Compared to Healthy Individuals and in Relation to Immunosuppressive Treatment
Joan Raouf¹, Helena Idborg¹, Petter Olsson², Per Johan Jakobsson¹, Ingrid E. Lundberg¹ and Marina Korotkova¹, ¹Medicine, Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet S-171 76, Stockholm, Sweden, Stockholm, Sweden, ²Analytical Chemistry, Department of Analytical Chemistry, Stockholm University, Sweden, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases, characterized by muscle fatigue. Despite conventional immunosuppressive treatment including high doses of glucocorticoids, only a…
Abstract Number: 831 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Decreases the Frequency of Endoscopic Therapy for Gastric Antral Vascular Ectasia in Patients with Systemic Sclerosis
Tiffany Lin¹, James Bena², Shannon Morrison² and Soumya Chatterjee³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Gastric antral vascular ectasia (GAVE) is an increasingly recognized cause of upper gastrointestinal bleeding in patients with systemic sclerosis (SSc). These patients may require…
Abstract Number: 923 • 2015 ACR/ARHP Annual Meeting
Perceptions of Infectious Risk of Immunosuppressive Medications Among Treating Physicians
Rebecca Sharim¹, Leny Mathew², Michael George³, Preethi Thomas⁴ and Misha Rosenbach⁵, ¹Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Physicians often encounter patients who are treated with immunosuppressive agents and must consider the risk of infection that the medications may pose. We explored…
Abstract Number: 1397 • 2015 ACR/ARHP Annual Meeting
Successful Treatment of Cardiac Sarcoidosis with Biologic and Immunosuppressive Combination Therapy
Maya Estephan¹, Mehrdad Maz², Mark Hamblin³ and Julian Magadan¹, ¹Division of Allergy, Clinical Immunology, and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS, ³Pulmonary and Critical Care Medicine, ILD Clinic, University of Kansas Medical Center, Kansas city, KS
Background/Purpose: Although cardiac involvement is symptomatic in only 5% of patients with sarcoidosis, it is considered an important prognostic factor and the second leading cause…
Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Matthew Wong-Pack¹, Rod Rodjanapiches¹, Arthur Lau^1,2,3, George Ioannidis^1,3, Sally Wade⁴, Leslie Spangler⁴, Celia JF Lin⁴, Patrick Roy-Gayos¹, William G Bensen^1,3, Robert Bensen³ and Jonathan D Adachi^1,3, ¹McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…
Abstract Number: 1988 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Mizoribine for Polymyalgia Rheumatica: Analysis of 47 Cases
Ryo Rokutanda¹, Chisun Min², Yuko Kataoka¹, Tokutaro Tsuda¹, Shunya Kaneshita¹, Ken-ichi Yamaguchi³, Koji Takasugi⁴, Masei Suda¹, Akira Takeda³, Yukio Matsui^1,3, Mitsumasa Kishimoto¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ³Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁴Imuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease characterized by aching and morning stiffness of body, which is seen almost exclusively in adults over…
Abstract Number: 2502 • 2015 ACR/ARHP Annual Meeting
Implementation of New Pneumococcal Vaccination Recommendations in an Academic Rheumatology Clinic
Alison Bays¹, Renuka Nayak², David I. Daikh³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, UCSF, San Francisco, CA, ³Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ⁴Rheumatology, UCSF, SF, CA, ⁵San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Invasive pneumococcal disease is approximately four times more common among patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) compared to healthy counterparts.…
Abstract Number: 3193 • 2015 ACR/ARHP Annual Meeting
Immunomodulatory and Antiviral Therapies in a Mouse Model of Chikungunya Viral Arthritis
Jonathan Miner¹, Lindsey Cook¹, Raeann Shimak², Julie Fox¹, Alissa Young¹, Kristen Monte², Subhajit Poddar², Michael Diamond¹ and Deborah Lenschow¹, ¹Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, MO, ²Washington University in Saint Louis School of Medicine, Saint Louis, MO
Background/Purpose: Chikungunya virus (CHIKV) is a rapidly emerging arthritogenic mosquito-borne alphavirus that has infected more than 1 million individuals in the Western Hemisphere since 2014. …
Abstract Number: 3262 • 2015 ACR/ARHP Annual Meeting
The Influence of Immunosuppressive Therapy on Microangiopathy in Systemic Sclerosis As Measured with Nailfoldcapillaroscopy
Jessica Meijs¹, B. de Boer¹, Anne Schouffoer^1,2, T. W. J. Huizinga³, Hein Putter⁴ and Jeska K. de Vries-Bouwstra¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Haga Hospital, The Hague, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Medical Statitics and Bioinformatics, professor in medical statistics, Leiden, Netherlands
Background/Purpose: Microangiopathy in systemic sclerosis (SSc), as visualized by nailfold videocapillaroscopy (NVC) is a dynamic and sequential process1. In time, NVC patterns progress from early,…
Abstract Number: 1677 • 2014 ACR/ARHP Annual Meeting
Association of Gastrointestinal Symptoms with Immunosuppressant Use in the Prospective Registry of Early Systemic Sclerosis Cohort
Tracy M. Frech¹, Maureen Murtaugh², Ami A. Shah³, Jessica K. Gordon⁴, Victoria K. Shanmugam⁵, Robyn T. Domsic⁶, Monique Hinchcliff⁷, Faye N. Hant⁸, Shervin Assassi⁹, Virginia D. Steen¹⁰ and Dinesh Khanna¹¹, ¹Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ²Internal Medicine-Division of Epidemiology, University of Utah School of Medicine, SLC, UT, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, The George Washington University, Washington, DC, ⁶Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Dept of Medicine, Medical Univ of South Carolina, Charleston, SC, ⁹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹⁰Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹¹University of Michigan Health System, Ann Arbor, MI
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) is a multicenter incident cohort study of patients with early diffuse cutaneous systemic sclerosis (dcSSc; <…
Abstract Number: 1661 • 2014 ACR/ARHP Annual Meeting
Are Repeat Renal Biopsies Important in Managing Lupus Nephritis Flares?
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose Lupus nephritis (LN) is the major cause of morbidity and mortality in patients with systemic lupus erythematosus. The role of repeat kidney biopsies (RB)…
Abstract Number: 1260 • 2014 ACR/ARHP Annual Meeting
The Early Use of Cyclosporine Is Beneficial for Long-Term Prognosis in Patients of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease with Anti- Synthetase Antibodies
Yuji Hosono¹, Ran Nakashima², Yoshitaka Imura³, Naoichiro Yukawa², Hajime Yoshifuji², Takaki Nojima⁴, Koichiro Ohmura² and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Interstitial lung disesases (ILD) is the most common cause of mortality in polymyosotis (PM) and dermatomyositis (DM). Cyclosporine had been reported to improve clinical…
Abstract Number: 1051 • 2014 ACR/ARHP Annual Meeting
Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta-Analysis
Jasvinder A. Singh¹, Ahmed Kotb², Alomgir Hossain², Amy Mudano³ and George Wells⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Ottawa, Ottawa, ON, Canada, ³Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁴Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose To compare renal remission rates with immunosuppressives by performing a systematic review and network meta-analyses (NMA) of RCTs of lupus nephritis. Methods We performed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.